Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olmesartan medoxomil - Daiichi Sankyo Company

Drug Profile

Olmesartan medoxomil - Daiichi Sankyo Company

Alternative Names: Alteis; Benetor; Benevas; Benicar; Cardosal; CS 866; CS 866RN; CS-866DM; DE-092; Ixia; Mencord; Olmec; Olmes; Olmesartan; Olmetec; Olmighty; Olvance™; Omesar; Openvas; RNH-6270; Tensonit; Votum

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer AbbVie; Daewoong Pharmaceutical; Daiichi Sankyo Company; Menarini; Merck & Co; Pfizer; Sun Pharmaceutical Industries
  • Class Antihypertensives; Eye disorder therapies; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 18 Jan 2022 Olmesartan medoxomil licensed to Cosette Pharmaceuticals in USA
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 28 Aug 2018 Daiichi Sankyo Company completes a phase II trial in Hypertension (In adolescents, In adults, In the elderly) in Japan (PO) (UMIN000015323)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top